|
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer Clinical research trials and Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer. Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer clinical trial. Participants frequently get the best healthcare available for their Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer  Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
For Condition: stage 2 prostate cancer,stage 3 prostate cancer,stage 1 prostate cancer,adenocarcinoma of the prostate
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Cancer and Leukemia Group B
Synopsis: RATIONALE: Imaging procedures such as MRI may improve the ability to determine the response of prostate tumors to therapy. PURPOSE: Phase II trial to study MRI results in patients with prostate cancer that has been treated with radiation therapy plus androgen suppression therapy.
Details: OBJECTIVES: I. Establish whether changes between baseline and 2-month post androgen suppression endorectal coil MRI results predict for biochemical control following radiotherapy with androgen suppression in patients with adenocarcinoma of the prostate. PROTOCOL OUTLINE: Patients undergo a baseline endorectal coil MRI, followed by total androgen suppression (TAS) with either leuprolide IM or subcutaneous goserelin once a month plus oral flutamide 3 times a day for 2 months. Patients then receive a second endorectal coil MRI, followed by 2 months of external-beam radiotherapy plus TAS. Patients may receive an additional 2 months of TAS at the discretion of the treating physician. Patients are followed every 6 months for 3 years, then yearly thereafter. PROJECTED ACCRUAL: Approximately 180 patients (approximately 60 per year) will be accrued for this study over a 34 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 30 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed adenocarcinoma of the prostate; AJCC stage T1b-T4b, N0 or Nx, M0; Transrectal, transperineal, or transurethral biopsy required --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: No prior chemotherapy for carcinoma of the prostate - Endocrine therapy: No prior androgen deprivation therapy (medical or surgical) - Radiotherapy: No prior radiation therapy for carcinoma of the prostate - Surgery: No prior surgical androgen deprivation therapy --Patient Characteristics-- - Age: 30 and over - Performance status: CALGB 0-2 - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified - Other: The following may increase the risk of protocol treatment: Serious intercurrent medical illness that might compromise patient safety; Active acute infection requiring antibiotics; Suppression therapy for chronic urinary tract infection allowed; Uncontrolled or severe cardiovascular disease; Psychiatric conditions that prevent compliance or informed consent
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AnthonyD'Amico, Study Chair, Cancer and Leukemia Group B
Joint Center for Radiation Therapy
Boston, Massachusetts, 02215
United States
Medical University of South Carolina
Charleston, South Carolina, 29425-0721
United States
Walter Reed Army Medical Center
Washington D.C., District of Columbia, 20307-5000
United States
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210
United States
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
University of Chicago Cancer Research Center
Chicago, Illinois, 60637
United States
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
United States
St. Joseph's Hospital and Medical Center
Paterson, New Jersey, 07503
United States
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
Winston Salem, North Carolina, 27157-1082
United States
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
United States
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, 94115-0128
United States
Additional Information:
Study ID Numbers: CDR0000065212; CLB-9682
Study Start Date: May 1997
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002889
Other Stage 3 Prostate Cancer Studies:
1. Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
2. Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer
3. Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer
4. Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
5. Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer
Related Studies:
Other stage 3 prostate cancer Clinical Trials
Other North Carolina Clinical Trials
Other Winston Salem Clinical Trials
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
|
|
|
|
|
|
|
|
